Johnson & Johnson (JNJ) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for JNJ is $276.00 — 3.8% above the latest price of $265.83.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bull case for JNJ is underpinned by its innovative product pipeline and strategic growth initiatives. Excluding the impact of Stelara, the business is demonstrating double-digit growth. Recent FDA approval for the OTTAVA surgical robot and new drug approvals like ICOTYDE for psoriasis and VARIPULSE Pro in Europe are expected to drive future revenue. Strong performance in key segments such as oncology (Darzalex, Carvykti, Tecvayli) and immunology (Tremfya) continues to fuel growth. JNJ's commitment to achieving double-digit growth by the end of the decade, combined with its status as a defensive compounder with a consistent dividend, makes it an attractive long-term holding.
Bear Case
The bear case suggests that JNJ's current valuation may be stretched, with some valuation models indicating it is significantly overvalued; for instance, a DCF earnings-based intrinsic value of $123.97 compared to its current price of $268.04. Analysts' mean price targets generally offer limited upside from current levels, with one model implying only a 1% annualized return until 2030. The company faces intense competition in key markets, such as the pharmaceutical market in China for its psoriasis treatment. While major litigations have been addressed, ongoing legal challenges could still pose headwinds. The reliance on new product launches to offset declining sales of established drugs like Stelara presents a continuous challenge.
Model-assessed risk level: Low
Key Catalysts to Watch
Further advancements and approvals in its innovative medicine pipeline, particularly in oncology and immunology.
Successful global commercialization and adoption of new MedTech products, such as the OTTAVA surgical robot.
Strategic acquisitions or partnerships that expand its market reach or product portfolio.
Continued robust financial performance, exceeding guidance and analyst expectations.
Upcoming Enterprise Business Review in December 2026, which could outline future growth strategies.
Technical Backdrop
RSI-14
52.7
50-Day MA
$258.78
200-Day MA
$219.65
From 52-Wk High
-2.8%
Full momentum breakdown: Is JNJ overbought or oversold?
Model Notes
Johnson & Johnson (JNJ) is a global healthcare giant with diversified operations in Innovative Medicine and MedTech. The company reported strong Q2 2026 results, exceeding sales and EPS estimates, and subsequently raised its full-year 2026 guidance. JNJ is on track to achieve over $100 billion in annual revenue for the first time in its history. The stock has shown remarkable performance, rising over 50% in the past year, outperforming the broader market. Key risks, such as a significant talc settlement and FDA approval for its OTTAVA surgical robot, have been cleared, reducing long-standing overhangs. Despite a consensus 'Moderate Buy' rating from analysts, some valuation models suggest the stock may be overvalued at current prices.
JNJ stock has demonstrated a strong uptrend over the past year, surging 53% to $268.04 as of August 28, 2026. In 2026 alone, the stock is up 29.5%, consistently trading above its 50-day and 200-day moving averages, indicating a sustained bullish momentum. The stock recently reached an all-time high of $276.47 on August 19, 2026, and is currently trading just 3.1% below that peak. Despite significant price gains, its volatility has remained moderate.
Current Street Context
August 31, 2026The AI price target for Johnson & Johnson is $276.00. This target aligns with recent analyst sentiment, which has been largely positive following the company's strong second-quarter 2026 earnings. Johnson & Johnson reported an EPS of $2.90, beating estimates, and robust revenue growth. Analysts anticipate continued earnings growth, projecting a 10.25% increase next year, from $11.61 to $12.80 per share. The next significant event for JNJ is its third-quarter 2026 earnings release, estimated for October 13, 2026, with an expected EPS of $2.95, representing a 5.36% year-over-year increase. Recent analyst reports have also highlighted JNJ as a top dividend stock, which could contribute to its appeal. Investors should remember that price targets are estimates and actual results may vary.
Frequently Asked Questions
What is the price target for JNJ?
How is this forecast generated?
How accurate are stock price predictions?
Will JNJ stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews JNJ’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on JNJ
Johnson & Johnson Overview
Price, chart, analysis & financials
JNJ: Overbought or Oversold?
Updated daily
JNJ: Why Is It Moving?
Updated daily
JNJ: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers